Canaccord raised the firm’s price target on Alnylam to $357 from $283 and keeps a Buy rating on the shares. The firm said after HELIOS-B’s topline win, they updated its model to bring it more inline with recent physician feedback. Canaccord said they are modeling a price in- line with Vyndaquel/Vyndamax and are increasing peak market share to 35% from 20%; which could still be conservative according to their survey.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
Questions or Comments about the article? Write to editor@tipranks.com